Flavonol and imidazole derivatives block HPV16 E6 activities and reactivate apoptotic pathways in HPV+ cells

Cell Death and Disease

Volumn 7, Issue 1, 2016, Pages

  Yuan, C H ^a   Filippova, M ^a   Krstenansky, J L ^b   Duerksen Hughes, P J ^a  

^a LOMA LINDA UNIVERSITY   (United States)

^b Department of Biopharmaceutical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CASPASE 3; CASPASE 7; CASPASE 8; CISPLATIN; DOXORUBICIN; IMIDAZOLE DERIVATIVE; MYRICETIN; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; FLAVONOID; FLAVONOL DERIVATIVE; ONCOPROTEIN; PYRIDINE DERIVATIVE; REPRESSOR PROTEIN; SPINACINE;

ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER PATIENT; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; UTERINE CERVIX CARCINOMA; WART VIRUS; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CELL LINE; DRUG EFFECTS; DRUG POTENTIATION; HEAD AND NECK NEOPLASMS; METABOLISM; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL LINE, TUMOR; CISPLATIN; DOXORUBICIN; DRUG SYNERGISM; FLAVONOIDS; FLAVONOLS; HEAD AND NECK NEOPLASMS; HUMANS; IMIDAZOLES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PYRIDINES; REPRESSOR PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 85014005327     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.391     Document Type: Article

References (38)

1. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
2. Adams AK, Wise-Draper TM, Wells SI. Human papillomavirus induced transformation in cervical and head and neck cancers. Cancers (Basel) 2014; 6: 1793-1820.
3. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 1985; 3: 1079-1085.
4. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. Cancer 1981; 48: 899-903.
5. Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr, Hatch KD. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol Oncol 1989; 32: 198-202.
6. Scatchard K, Forrest JL, Flubacher M, Cornes P, Williams C. Chemotherapy for metastatic and recurrent cervical cancer. Cochrane Database Syst Rev 2012; 10: CD006469.
7. Lee TY, Jeung YJ, Lee CJ, Kim HY, Kim SH, Kim WG. Promising treatment results of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage 1B cervical cancer. Obstet Gynecol Sci 2013; 56: 15-21.
8. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
9. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003; 9: 3731-3741.
10. Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003; 21: 3526-3534.
11. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954-960.
12. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H et al. Isotypedependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001; 166: 4891-4898.
13. Tanaka S, Sugimachi K, Shirabe K, Shimada M,Wands JR. Expression and antitumor effects of TRAIL in human cholangiocarcinoma. Hepatology 2000; 32: 523-527.
14. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: The promises and the challenges. Rev Recent Clin Trials 2009; 4: 34-41.
15. El-Zawahry A, McKillop J, Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 2005; 5: 2.
16. Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study. Clin Cancer Res 2009; 15: 5584-5590.
17. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002; 62: 5800-5806.
18. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991; 10: 4129-4135.
19. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505.
20. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136.
21. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991; 10: 4129-4135.
22. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991; 67: 547-556.
23. Lechner MS, Laimins LA. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 1994; 68: 4262-4273.
24. Tungteakkhun SS, Filippova M, Fodor N, Duerksen-Hughes PJ. The full-length isoform of human papillomavirus 16 E6 and its splice variant E6 bind to different sites on the procaspase 8 death effector domain. J Virol 2010; 84: 1453-1463.
25. Filippova M, Parkhurst L, Duerksen-Hughes PJ. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J Biol Chem 2004; 279: 25729-25744.
26. Filippova M, Johnson MM, Bautista M, Filippov V, Fodor N, Tungteakkhun SS et al. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J Virol 2007; 81: 4116-4129.
27. Garnett TO, Filippova M, Duerksen-Hughes PJ. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ 2006; 13: 1915-1926.
28. Yuan CH, Filippova M, Tungteakkhun SS, Duerksen-Hughes PJ, Krstenansky JL. Small molecule inhibitors of the HPV16-E6 interaction with caspase 8. Bioorg Med Chem Lett 2012; 22: 2125-2129.
29. Garnett TO, Filippova M, Duerksen-Hughes PJ. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ 2006; 13: 1915-1926.
30. D'Abramo CM, Archambault J. Small molecule inhibitors of human papillomavirus protein - protein interactions. Open Virol J 2011; 5: 80-95.
31. Phelps WC, Barnes JA, Lobe DC. Molecular targets for human papillomaviruses: Prospects for antiviral therapy. Antiviral Chem Chemother 1998; 9: 359-377.
32. Hebner C, Beglin M, Laimins LA. Human papillomavirus E6 proteins mediate resistance to interferon-induced growth arrest through inhibition of p53 acetylation. J Virol 2007; 81: 12740-12747.
33. Tungteakkhun SS, Filippova M, Neidigh JW, Fodor N, Duerksen-Hughes PJ. The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain. J Virol 2008; 82: 9600-9614.
34. Liu Y, Liu Z, Androphy E, Chen J, Baleja JD. Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus. Biochemistry 2004; 43: 7421-7431.
35. Baleja JD, Cherry JJ, Liu Z, Gao H, Nicklaus MC, Voigt JH et al. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res 2006; 72: 49-59.
36. Rein DT, Kurbacher CM. The role of chemotherapy in invasive cancer of the cervix uteri: Current standards and future prospects. Anticancer Drugs 2001; 12: 787-795.
37. Tungteakkhun SS, Filippova M, Fodor N, Duerksen-Hughes PJ. The full-length isoform of human papillomavirus 16 E6 and its splice variant E6∗ bind to different sites on the procaspase 8 death effector domain. J Virol 2010; 84: 1453-1463.
38. Filippova M, Parkhurst L, Duerksen-Hughes PJ. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J Biol Chem 2004; 279: 25729-25744.